Is Indoco Remedies Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Indoco Remedies Ltd (INDOCO.NS) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Indoco Remedies Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Indoco Remedies Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Indoco Remedies Ltd?

Muslim investors may consider investing in Indoco Remedies Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Indoco Remedies Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Indoco Remedies Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Indoco Remedies Ltd updated?

The Shariah compliance status of Indoco Remedies Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Indoco Remedies Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Indoco Remedies Ltd?

You can check the latest Shariah compliance status of Indoco Remedies Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

INDOCO.NS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: December 23, 2025

Report Source: 2026 2nd Quarter Report

Indoco Remedies Ltd. Stock Analysis INDOCO.NS

India Health Care Micro Cap Report: Q2, 2026

Indoco Remedies Ltd. engages in manufacturing and marketing of Formulations (Finished Dosage Forms) and active pharmaceutical ingredients. The firm is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The firm caters to both Domestic and International markets. Its products include SENSODENT-K, HOMIDE, DEXOREN-S, LORCHEK-MR, SENSOFORM, KIDODENT, NINAF, KARVOL PLUS, CYCLOPAM, LIGNOX+ADRENLINE, NOXA, CITAL-UTI, RENOLEN, REXIDIN-M, CITAL, SENSODENT-KF, CARMICIDE, TOBAREN-DM, FEBREX PLUS, SCABEX, CLOBEN-G, MOFLOREN-BF, OTOREX, ZINCOREN, SENOLIN, LIGNOX, HEMSYL, FEDRIS, REXIDIN, VEPAN, OXIPOD, TURBOCORT, MACUCHEK, and DENTOGEL. The firm has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.

Key Statistics of Indoco Remedies Ltd (INDOCO.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹223.31₹230.00

Today's Open

₹223.31

Volume

38.66K

P/E Ratio (TTM)

52 Week Range

₹162.19₹349.80

Market Cap

19.46B

Avg. Volume

127.08K

Dividend Yield

0.14%

Financial Metrics & Statements of Indoco Remedies Ltd (INDOCO.NS)

FAQ's for Indoco Remedies Ltd (INDOCO.NS)

According to Musaffa’s Shariah screening methodology, Indoco Remedies Ltd (INDOCO.NS) is currently classified as NOT HALAL as of December 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.